Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;26(9):2661.
doi: 10.3390/molecules26092661.

New Hybrids Based on Curcumin and Resveratrol: Synthesis, Cytotoxicity and Antiproliferative Activity against Colorectal Cancer Cells

Cristian Hernández  1 , Gustavo Moreno  1 , Angie Herrera-R  1 , Wilson Cardona-G  1
Affiliations

New Hybrids Based on Curcumin and Resveratrol: Synthesis, Cytotoxicity and Antiproliferative Activity against Colorectal Cancer Cells

Cristian Hernández et al. Molecules. .

Abstract

We synthesized twelve hybrids based on curcumin and resveratrol, and their structures were elucidated by spectroscopic analysis. The chemopreventive potential of these compounds was evaluated against SW480 human colon adenocarcinoma cells, its metastatic derivative SW620, along with the non-malignant CHO-K1 cell line. Among the tested compounds, hybrids 3e and 3i (for SW480) and 3a, 3e and 3k (for SW620) displayed the best cytotoxic activity with IC50 values ranging from 11.52 ± 2.78 to 29.33 ± 4.73 µM for both cell lines, with selectivity indices (SI) higher than 1, after 48 h of treatment. Selectivity indices were even higher than those reported for the reference drug, 5-fluorouracil (SI = 0.96), the starting compound resveratrol (SI = 0.45) and the equimolar mixture of curcumin plus resveratrol (SI = 0.77). The previous hybrids showed good antiproliferative activity.

Keywords: antiproliferative activity; colorectal cancer; curcumin; cytotoxicity; hybrid molecules; resveratrol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Hybrid molecules derived from curcumin and resveratrol with anticancer activity.
Figure 2
Figure 2
Design of hybrids based on curcumin and resveratrol as anti-cancer agents.
Scheme 1
Scheme 1
Synthesis of hybrids based on curcumin and resveratrol.
Figure 3
Figure 3
Antiproliferative effect of hybrids based on curcumin and resveratrol against: SW480 cell line (A); and its metastatic derivative SW620 cell line (B). Data are presented as the mean ± SE of at least three independent experiments (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). Vehicle control was assumed as 100% of viability.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Rejhová A., Opattová A., Čumová A., Slíva D., Vodička P. Natural compounds and combination therapy in colorectal cancer treatment. Eur. J. Med. Chem. 2018;144:582–594. doi: 10.1016/j.ejmech.2017.12.039. - DOI - PubMed
    1. Feng T., Wei Y., Lee R.J., Zhao L. Liposomal curcumin and its application in cancer. Int. J. Nanomed. 2017;12:6027–6044. doi: 10.2147/IJN.S132434. - DOI - PMC - PubMed
    1. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer. Res. 2003;23:363–398. - PubMed
    1. Mirzaei H., Masoudifar A., Sahebkar A., Zare N., Nahand J.S., Rashidi B., Mehrabian E., Mohammadi M., Mirzaei H.R., Jaafari M.R. MicroRNA: A novel target of curcumin in cancer therapy. J. Cell. Physiol. 2018;233:3004–3015. doi: 10.1002/jcp.26055. - DOI - PubMed

MeSH terms